Board of directors

The board of directors was elected at the Annual General Meeting on May 6, 2021 and consists of 6 persons. The board has appointed an audit committee and a remuneration committee, each consisting of 3 persons. A summary of the board members is found in the table below and a presentation of each member is found below.

NameBoard functionAudit committeeRemuneration committee
Gunnar OlssonChairChair
Carola LemneVice chairMember
Lars AdlerssonMemberMember
Martin NicklassonMemberMember
Rein PiirMemberChair
Lena TorlegårdMemberMember

Gunnar Olsson

Chair, born 1953
Member of Board since: 2017

Education and background: MD and PhD in Medicine, Karolinska Institutet and education at IMD, Lausanne, Switzerland. 25 years of experience in senior positions within AstraZeneca, among others in the management team for Global Cardiovascular and Gastrointestinal R&D as well as 10 years as manager for the same unit. Been involved in the development and launch of seven global blockbusters/mega brands.

Other ongoing assignments: Chair in Athera Biotechnologies AB. Board member in Olsson Solutions AB, Gesynta Pharma AB and Hjärt-Lungfonden.

Shareholding: 2,000 Class A shares.

Independent of the company, its management and major shareholders: Yes.

Carola Lemne

Vice Chair, born 1958
Member of Board since: 2019

Education and background: MD, PhD and an associate professor at Karolinska Institute. Previously CEO of the Confederation of Swedish Enterprise (Swe: Svenskt Näringsliv) and Danderyd University Hospital, as well as president and CEO of Praktikertjänst AB and clinical research manager and manager at Pharmacia Corp. Carola Lemne has previously served on the boards of Getinge, Apoteket, MEDA, Investor and AFA Insurance, as well as board member of the foundation for strategic research ‘Statliga delegationen för klinisk forskning’, Stockholm university, the institute ‘Institutet för Näringslivsforskning’ and the Swedish Corporate Governanace Board, and chair of the board for the education council for clinical trials (Swe: Svenska Utbildningsrådet för Klinisk Prövning at Uppsala University.

Other ongoing assignments: Board member of Young Achievement Sweden (Swe: UF, UngFöretagsamhet), the international English School in Sweden Holdings II AB and Art Clinic Holding AB. Chair of the board of Arjo AB and Calgo Enerprise AB. Principal and board member for HM the King Gustav V Tercentenary Foundation.

Holdings: 9,000 Class A shares.

Independent of the company, its management and major shareholders: Yes.

Lars Adlersson

born 1964
Member of Board since: 2017

Education and background: MBA from Uppsala university and has also graduated from strategy and management education at Duke University, London Business School and IFL Executive Education. 30 years of experience from the life science industry, including as CEO at Medivir, Managing Director GlaxoSmithKline, Austria and Sweden, and Senior Analyst at Handelsbanken Capital Markets. Lars Adlersson is currently Partner and Senior adviser at Adlersson Health AB.

Other ongoing assignments: Chair Sweden-BIO Service AB, Adlersson Heath AB and the housing cooperative (Swe: bostadsrättsföreningen) Östbra.

Shareholding: 3,000 Class A shares.

Independent of the company, its management and major shareholders: Yes.

Martin Nicklasson

born 1955
Member of Board since: 2021

Education and background: More than 40 years of experience within Life Sciences with about 25 years in executive positions at AstraZeneca and Kabi Pharmacia, e.g. CEO Astra Pain Control AB, CEO Astra Hässle AB and member of AstraZeneca’s group management team. He has been the CEO of Biovitrum AB and Sobi AB and has an extensive experience of several boards within the Life Sciences in Sweden, Norway, Denmark, Switzerland and the UK and US. He is a certified pharmacist, holds a Ph.D. in Pharmaceutical Technology and is an associate professor in Pharmaceutical Technology from University of Uppsala.

Other ongoing assignments: Chair of the Board in Zealand Pharma A/S and board member in Basilea Pharmaceutica Ltd.

Shareholding: 2,000 Class A shares.

Independent of the company, its management and major shareholders: Yes.

Rein Piir

born 1958
Member of Board since: 2016

Education and background: B.Sc. Business Economics and Management, Uppsala University. Many years’ experience in advising on capital market issues, including positions as head of analysis at Carnegie Investment Bank AB and strategist at Alecta. Other positions include CFO/IR manager in the public company Medivir and auditor PricewaterhouseCoopers AB. He is Vice President of IR in the public company Camurus AB and Alligator Bioscience AB.

Other ongoing assignments: Chair Piir & Partner AB. Board member in L.E. Svensson Snickeri AB.

Shareholding: 36,333 Class A shares, 5,567 Class B shares and 5,009 warrants that is equivalent to 25,045 Class A shares, through legal entities/relatives.

Independent of the company, its management and major shareholders: Yes.

Lena Torlegård

born 1963
Member of Board since: 2018

Education and background: MBA from Stockholm University (Handelshögskolan). Lena Torlegård has been an advisor for financial and corporate communications in a large number of companies, including companies in the life science industry.

Other ongoing assignments: Board member in Codesign Sweden AB, Nanologica AB (publ), IRLAB Sweden, Annexin Pharmaceuticals AB (publ), Synartro AB and Lena Torlegård AB.

Shareholding: 7,312 Class A shares.

Independent of the company, its management and major shareholders: Yes.

Ongoing assignments refer to the assignments registered with the Swedish Companies Registration Office (Swe: Bolagsverket) as of April 12, 2021 and do not include assignments within the IRLAB companies. Shareholding refers to holdings registered in the share register kept at Euroclear Sweden AB on February 29, 2020, adjusted for changes known by IRLAB until May 7, 2021.